April 19, 2017 — To further support clinicians in their fight against chronic liver disease, Echosens and GE Healthcare have joined forces to offer a new integrated system, the Logiq S8 XDclear 2.0 ultrasound system, which will be presented at the International Liver Congress, April 19-23 in Amsterdam. Combining liver tissue quantification and ultrasound technologies, this platform provides a wider range of solutions for the screening, diagnosis and monitoring of liver diseases.
Chronic liver disease represents a major and rising public healthcare issue, affecting more than one billion people worldwide. It can be caused by a virus, such as hepatitis B or C, by excessive alcohol consumption or by dietary habits, resulting in conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
These diseases generally remain symptomless and undetected until their very late stages but they progressively worsen over time and might ultimately lead to life-threatening complications, such as liver cirrhosis and liver cancer.
Echosens has developed FibroScan, the reference quantitative tool for the management of patients with chronic liver disease. FibroScan technology provides ultrafast and painless measurements of liver fibrosis, cirrhosis and steatosis, which are key parameters to assess liver condition. Recommended in the guidelines of prominent clinical organizations, including the World Health Organization (WHO), it has brought a non-invasive and cost-efficient alternative to painful liver biopsies, where a clinician inserts a needle into the liver to collect a tissue sample.
The Logiq S8 XDclear 2.0 is GE Healthcare's premium ultrasound system for a wide range of clinical uses. It offers a comprehensive Liver Package which, paired with FibroScan, now gives clinicians a powerful tool to see and quantify liver diseases in a single exam, supporting them with increased confidence and broader patient coverage.
The system may not be available in all regions.